OTCMKTS:OSIR - Osiris Therapeutics Stock Price, Price Target & More

$7.50 -0.28 (-3.60 %)
(As of 04/24/2018 02:57 AM ET)
Previous Close$7.78
Today's Range$7.01 - $7.77
52-Week Range$4.20 - $9.98
Volume14,316 shs
Average Volume30,787 shs
Market Capitalization$268.61 million
P/E RatioN/A
Dividend YieldN/A
Beta0.54

About Osiris Therapeutics (OTCMKTS:OSIR)

Osiris Therapeutics logoOsiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.

Receive OSIR News and Ratings via Email

Sign-up to receive the latest news and ratings for OSIR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolOTCMKTS:OSIR
CUSIP68827R10
Phone443-545-1800

Debt

Debt-to-Equity RatioN/A
Current Ratio2.08%
Quick Ratio1.76%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$118.51 million
Price / Sales2.19
Cash FlowN/A
Price / CashN/A
Book Value$1.20 per share
Price / Book6.25

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees350
Outstanding Shares34,530,000

How to Become a New Pot Stock Millionaire

Osiris Therapeutics (OTCMKTS:OSIR) Frequently Asked Questions

What is Osiris Therapeutics' stock symbol?

Osiris Therapeutics trades on the OTCMKTS under the ticker symbol "OSIR."

Who are some of Osiris Therapeutics' key competitors?

Who are Osiris Therapeutics' key executives?

Osiris Therapeutics' management team includes the folowing people:
  • Mr. Philip R. Jacoby Jr., Interim Principal Accounting Officer (Age 65)
  • Mr. Jason Keefer, Interim CEO & Pres (Age 46)
  • Ms. Linda L. Chang, Chief Financial Officer (Age 52)
  • Dr. Alla N. Danilkovitch Ph.D., Chief Scientific Officer (Age 54)
  • Mr. Richard Skow, Gen. Counsel & Corp. Sec.

Has Osiris Therapeutics been receiving favorable news coverage?

Media headlines about OSIR stock have trended somewhat positive on Tuesday, Accern Sentiment reports. Accern rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Osiris Therapeutics earned a media sentiment score of 0.11 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 47.96 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of Osiris Therapeutics?

Shares of OSIR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Osiris Therapeutics' stock price today?

One share of OSIR stock can currently be purchased for approximately $7.50.

How big of a company is Osiris Therapeutics?

Osiris Therapeutics has a market capitalization of $268.61 million and generates $118.51 million in revenue each year. Osiris Therapeutics employs 350 workers across the globe.

How can I contact Osiris Therapeutics?

Osiris Therapeutics' mailing address is 7015 ALBERT EINSTEIN DRIVE, COLUMBIA MD, 21046. The biotechnology company can be reached via phone at 443-545-1800 or via email at [email protected]


MarketBeat Community Rating for Osiris Therapeutics (OSIR)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  82 (Vote Outperform)
Underperform Votes:  142 (Vote Underperform)
Total Votes:  224
MarketBeat's community ratings are surveys of what our community members think about Osiris Therapeutics and other stocks. Vote "Outperform" if you believe OSIR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OSIR will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Osiris Therapeutics (OTCMKTS:OSIR) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
(Data available from 4/24/2016 forward)

Earnings

Osiris Therapeutics (OTCMKTS:OSIR) Earnings History and Estimates Chart

Earnings by Quarter for Osiris Therapeutics (OTCMKTS:OSIR)

Osiris Therapeutics (OTCMKTS OSIR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2015Q315$0.06($0.02)$25.40 million$24.30 millionViewN/AView Earnings Details
8/5/2015Q215$0.06$0.03$23.60 million$23.70 millionViewN/AView Earnings Details
5/8/2015Q115$0.04$18.40 million$21.00 millionViewN/AView Earnings Details
3/5/2015Q414$0.05$0.03$18.53 million$19.50 millionViewN/AView Earnings Details
11/7/2014Q314($0.01)$0.02$14.80 million$17.20 millionViewN/AView Earnings Details
8/7/2014Q214$0.16($0.04)$11.00 million$13.30 millionViewN/AView Earnings Details
5/12/2014($0.08)($0.02)$9.00 million$10.05 millionViewN/AView Earnings Details
3/5/2014Q413$0.65$0.11$7.50 million$8.10 millionViewN/AView Earnings Details
11/1/2013Q313($0.10)($0.05)$6.70 million$6.88 millionViewN/AView Earnings Details
8/5/2013Q2 2013($0.09)($0.11)$4.35 million$5.29 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.09)($0.08)$3.53 million$4.06 millionViewN/AView Earnings Details
3/6/2013Q4 2012($0.15)($0.08)ViewN/AView Earnings Details
11/5/2012Q312($0.14)($0.09)$1.89 million$2.15 millionViewN/AView Earnings Details
7/30/2012Q2 2012($0.15)($0.13)ViewN/AView Earnings Details
5/11/2012Q1 2012($0.09)($0.04)ViewN/AView Earnings Details
3/9/2012Q4 2011$0.11$0.15ViewN/AView Earnings Details
11/4/2011Q3 2011$0.10$0.12ViewN/AView Earnings Details
8/5/2011Q2 2011$0.12$0.11ViewN/AView Earnings Details
5/9/2011Q1 2011$0.11$0.12ViewN/AView Earnings Details
3/7/2011Q4 2010$0.09$0.13ViewN/AView Earnings Details
11/5/2010Q3 2010$0.04$0.14ViewN/AView Earnings Details
8/6/2010Q2 2010$0.01$0.05ViewN/AView Earnings Details
5/7/2010Q1 2010($0.01)$0.07ViewN/AView Earnings Details
2/24/2010Q4 2009$0.23($0.01)ViewN/AView Earnings Details
11/4/2009Q3 2009$0.06($0.21)ViewN/AView Earnings Details
8/6/2009Q2 2009($0.14)($0.26)ViewN/AView Earnings Details
5/7/2009Q1 2009$0.02($0.24)ViewN/AView Earnings Details
2/27/2009Q4 2008$3.12($0.37)ViewN/AView Earnings Details
11/4/2008Q3 2008$0.42($0.63)ViewN/AView Earnings Details
8/7/2008Q2 2008($0.49)($0.58)ViewN/AView Earnings Details
5/9/2008Q1 2008($0.42)($0.60)ViewN/AView Earnings Details
2/28/2008Q4 2007($0.33)($0.56)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Osiris Therapeutics (OTCMKTS:OSIR) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
9/17/2015special$0.209/14/20159/16/20159/30/2015
9/17/2015special$0.2010/14/201510/16/201510/30/2015
(Data available from 1/1/2013 forward)

Insider Trades

Osiris Therapeutics (OTCMKTS OSIR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 44.60%
Institutional Ownership Percentage: 0.28%
Insider Trading History for Osiris Therapeutics (OTCMKTS:OSIR)
Institutional Ownership by Quarter for Osiris Therapeutics (OTCMKTS:OSIR)

Osiris Therapeutics (OTCMKTS OSIR) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/27/2014Matthew Paul NeumayerInsiderSell3,750$16.10$60,375.00View SEC Filing  
5/21/2014Philip Jacoby, Jr.CFOSell15,947$15.43$246,062.2112,500View SEC Filing  
3/14/2014Michelle Leroux WilliamsInsiderSell61,934$14.09$872,650.06View SEC Filing  
11/25/2013Philip Jacoby, Jr.CFOSell18,372$15.99$293,768.2812,500View SEC Filing  
11/15/2013Michelle Leroux WilliamsInsiderSell24,500$15.50$379,750.00View SEC Filing  
8/20/2013Matthew Paul NeumayerInsiderSell11,375$19.75$224,656.25View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Osiris Therapeutics (OTCMKTS OSIR) News Headlines

Source:
DateHeadline
Osiris Therapeutics: RegeneratedOsiris Therapeutics: Regenerated
seekingalpha.com - April 9 at 5:27 PM
MiMedx Sinks After Conference Call, Marc Cohodes ThrowdownMiMedx Sinks After Conference Call, Marc Cohodes' Throwdown
seekingalpha.com - February 28 at 8:11 AM
Critical Analysis: Osiris Therapeutics (OSIR) vs. XOMA (XOMA)Critical Analysis: Osiris Therapeutics (OSIR) vs. XOMA (XOMA)
www.americanbankingnews.com - February 24 at 5:36 AM
MiMedx, Fast-Growing Developer of Tissue Graft Products, Didn’t Report Payments to DoctorsMiMedx, Fast-Growing Developer of Tissue Graft Products, Didn’t Report Payments to Doctors
www.wsj.com - February 22 at 5:41 PM
Global regenerative medicine market expected to be driven by increasing funding for research and developmentGlobal regenerative medicine market expected to be driven by increasing funding for research and development
www.marketwatch.com - February 20 at 8:12 AM
Osiris CEO, its fourth in two years, will depart companyOsiris' CEO, its fourth in two years, will depart company
www.bizjournals.com - February 7 at 8:51 AM
Osiris Appoints Willi Miesch to its Board of Directors, Change in CEOOsiris Appoints Willi Miesch to its Board of Directors, Change in CEO
finance.yahoo.com - February 7 at 8:51 AM
$50 Billion Regenerative Medicines Market, 2025$50 Billion Regenerative Medicines Market, 2025
www.bizjournals.com - January 25 at 3:40 PM
Osiris Therapeutics (OSIR) and Jazz Pharmaceuticals (JAZZ) Critical ComparisonOsiris Therapeutics (OSIR) and Jazz Pharmaceuticals (JAZZ) Critical Comparison
www.americanbankingnews.com - December 30 at 7:12 PM
Comparing SIGA Technologies (SIGA) and Osiris Therapeutics (OSIR)Comparing SIGA Technologies (SIGA) and Osiris Therapeutics (OSIR)
www.americanbankingnews.com - December 23 at 11:58 PM
Reviewing Mateon Therapeutics (MATN) & Osiris Therapeutics (OSIR)Reviewing Mateon Therapeutics (MATN) & Osiris Therapeutics (OSIR)
www.americanbankingnews.com - December 23 at 5:24 PM
Year in Review 2017: In a year of turnover, Under Armour sees the most changeYear in Review 2017: In a year of turnover, Under Armour sees the most change
www.bizjournals.com - December 22 at 10:27 AM
Reviewing SIGA Technologies (SIGA) & Osiris Therapeutics (OSIR)Reviewing SIGA Technologies (SIGA) & Osiris Therapeutics (OSIR)
www.americanbankingnews.com - December 15 at 3:32 PM
Update in Lawsuit for Investors in Osiris Therapeutics, Inc. (NASDAQ: OSIR) Shares Announced by Shareholders FoundationUpdate in Lawsuit for Investors in Osiris Therapeutics, Inc. (NASDAQ: OSIR) Shares Announced by Shareholders Foundation
finance.yahoo.com - November 28 at 4:34 PM
Windtree Therapeutics (WINT) versus Osiris Therapeutics (OSIR) Critical AnalysisWindtree Therapeutics (WINT) versus Osiris Therapeutics (OSIR) Critical Analysis
www.americanbankingnews.com - November 28 at 1:08 AM
Financial Survey: Senesco Technologies (SVON) versus Osiris Therapeutics (OSIR)Financial Survey: Senesco Technologies (SVON) versus Osiris Therapeutics (OSIR)
www.americanbankingnews.com - November 21 at 7:33 PM

SEC Filings

Osiris Therapeutics (OTCMKTS:OSIR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Osiris Therapeutics (OTCMKTS:OSIR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Osiris Therapeutics (OTCMKTS OSIR) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.